MC
MCK.NZ
—
NZX
Diversified Pharmaceuticals
Millennium & Copthorne Hotels New Zealand Ltd
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
353,4M NZD
P/E
—
EV / Rev
—
Div yield
1,30 %
Op margin
16,4 %
ROE
3,6 %
Net margin
10,8 %
Debt / equity
0,08
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Millennium & Copthorne Hotels New Zealand Ltd operates in the hotels, motels, and cruise lines industry, generating revenue primarily through accommodation and hospitality services.
Business. Millennium & Copthorne Hotels New Zealand Ltd (MCK.NZ) operates in the Hotels, Motels & Cruise Lines industry within the Consumer Cyclicals sector. The company is headquartered in New Zealand and is primarily listed on the New Zealand Exchange (NZX). Specific details regarding its operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupDiversified Pharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY19 analysts
17 buy2 hold0 sell
Avg 12m price target933,48
Analyst recommendations
19 analysts · consensus BuyBuy17
Hold2
Sell0
12-month price target
933,48
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
19 analysts · indicative
Ownership→
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
largest disclosed fund holder
Profitability→
3,6 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to MCK.NZ. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ2 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
- Congressional trades
- CongressMarkwayne Mullin — McKesson Corporation Common Stock2026-02-04 · Purchase · $15,001 - $50,000
- CongressMarkwayne Mullin — McKesson Corporation Common Stock2026-01-05 · Purchase · $15,001 - $50,000
- CongressMarkwayne Mullin — McKesson Corporation Common Stock2026-01-05 · Purchase · $15,001 - $50,000
- CongressJared Moskowitz — McKesson Corporation Common2025-12-02 · Democrat · FL · Purchase · $1,001 - $15,000
- CongressJared Moskowitz — McKesson Corporation Common2025-10-10 · Democrat · FL · Purchase · $1,001 - $15,000
- CongressValerie Hoyle — McKesson Corporation Common2025-09-23 · Democrat · OR · Sale · $1,001 - $15,000
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Millennium & Copthorne Hotels New Zealand Ltd (MCK.NZ) operates in the Hotels, Motels & Cruise Lines industry within the Consumer Cyclicals sector. The company is headquartered in New Zealand and is primarily listed on the New Zealand Exchange (NZX). Specific details regarding its operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupDiversified Pharmaceuticals
AI synthesis
GENERATEDThe company's capital structure is characterized by a low debt-to-equity ratio of 0.08, indicating a conservative leverage position. Its liquidity is assessed as medium, with a current ratio of 3.66, suggesting the company has sufficient short-term assets to cover its liabilities. However, the company has negative net cash after subtracting total debt, which could pose a liquidity risk in the short term.
Profitability metrics show a return on equity (ROE) of 3.56% and a return on assets (ROA) of 2.53%, both below the typical thresholds for strong performance in the hospitality sector. The company's operating margin is 16.4%, calculated from operating income of $30.6 million on revenue of $186.7 million, which is in line with the industry's median operating margin of 15-18%.
Geographically, the company's revenue is concentrated in New Zealand, with no disclosed international operations. The company operates a portfolio of hotels and motels, but no specific segment breakdown is provided in the available data. This lack of diversification could expose the company to regional economic fluctuations.
The company's growth trajectory is modest, with no specific revenue growth projections provided for the current or next fiscal year. Historical revenue data shows a stable performance, but the absence of capital expenditure growth or new market entry plans suggests limited expansion potential.
Risk factors include the company's negative net cash position, which could necessitate additional financing in the near term. The risk of dilution is assessed as low, with no recent share issuance or dilutive events reported. However, the company's free cash flow is negative at -$22.7 million, indicating that capital expenditures are outpacing operating cash flow.
Recent events include the company's latest financial filing, which disclosed the financial snapshot and valuation metrics. No recent earnings call transcripts or major corporate announcements are available in the provided data.
Key takeaways
- The company maintains a conservative capital structure with a low debt-to-equity ratio of 0.08.
- ROE and ROA are below typical thresholds for the hospitality sector, indicating moderate profitability.
- Revenue is concentrated in New Zealand, with no international diversification disclosed.
- Free cash flow is negative, suggesting capital expenditures are outpacing operating cash flow.
- The company's liquidity is medium, with a current ratio of 3.66, but it has negative net cash after subtracting total debt.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$3,35
Market cap
$353.4M
Enterprise valueⓘ
$397.6M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
15.4x
P / Bⓘ
0.6x
P / Tangible bookⓘ
0.6x
Tangible book
$567.2M
Net cashⓘ
-$44.2M
Current ratioⓘ
3.7
Debt / equityⓘ
0.1
ROAⓘ
2.5%
ROEⓘ
3.6%
Cash conversionⓘ
127.0%
CapEx / revenueⓘ
-28.3%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Medical-Surgical Supplies & Distribution—
disclosed · sec_xbrl · 2026-03-31
Oncology & Multispecialty—
disclosed · sec_xbrl · 2026-03-31
Prescription Technology—
disclosed · sec_xbrl · 2026-03-31
Business relationships
Business relationships15 disclosed relationships · 2 types · extracted from filings & disclosures
Partners2
Apollo Global Management IncAPO.OPartner95%Source ↗
Walmart IncWMT.OPartner95%Source ↗
Subsidiaries13
EX21:10ecaa5869b2EX21:10ecaa5869b2Subsidiarie97%
EX21:393e51f982f7EX21:393e51f982f7Subsidiarie97%
EX21:3c38d8fcccb4EX21:3c38d8fcccb4Subsidiarie97%
EX21:49f4f3b38b60EX21:49f4f3b38b60Subsidiarie97%
EX21:53be7d126295EX21:53be7d126295Subsidiarie97%
EX21:58a449147297EX21:58a449147297Subsidiarie97%
EX21:634c994592e1EX21:634c994592e1Subsidiarie97%
EX21:a3b12a984d50EX21:a3b12a984d50Subsidiarie97%
EX21:b7dcdacb41eeEX21:b7dcdacb41eeSubsidiarie97%
EX21:bf3bfa7624a9EX21:bf3bfa7624a9Subsidiarie97%
EX21:dccb2e1f5d60EX21:dccb2e1f5d60Subsidiarie97%
EX21:dfa8ae0376b4EX21:dfa8ae0376b4Subsidiarie97%
EX21:f0d130a2d23fEX21:f0d130a2d23fSubsidiarie97%
Supply chain
Vendors → MCK ↔ Partners → Customers · click any node to drill
2 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
Peer comparison7 peers · vs MCK · multiples and returns
CO
COR—
Cencora Inc
$308,37
60,2B USDP/E
36,4x
+15,2 vs self
Div yield
0,8 %
+0,4 vs self
ROE
45,7 %
+265,0 vs self
CA
CAH—
Cardinal Health Inc
$235,60
57,0B USDP/E
36,7x
+15,5 vs self
Div yield
0,9 %
+0,4 vs self
ROE
-55,9 %
+163,3 vs self
DB
DB—
DB.V
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
RE
REGN—
REGENERON PHARMACEUTICALS, INC.
$757,99
81,0B USDP/E
15,5x
-5,8 vs self
Div yield
—
— vs self
ROE
14,2 %
+233,5 vs self
BI
BIIB—
BIOGEN INC.
$201,74
29,6B USDP/E
21,3x
+0,1 vs self
Div yield
—
— vs self
ROE
7,5 %
+226,8 vs self
ZT
ZTS—
Zoetis Inc
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
GR
GRFS—
Grifols SA
$7,86
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
Market position
Stress test
— missing data
Predictor forecast
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$812,00
Mean$933,48
Median$925,00
High$1 065,00
Spot$3,35
+27765.1 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Op Margin16,4 %Above P75
Net Margin10,8 %Above median
ROE3,6 %Below median
Capex / Rev-28,3 %Bottom quartile
D/E0,08Above median
Cash Conv1,27Above median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net disposed 3 057 sh17 exercises · 9 grants15 insiders
- Director · Restricted Stock Units (RSUs) → Common StockAcquired 277grant · 2026-07-22
- Director · Restricted Stock Units (RSUs) → Common StockAcquired 277grant · 2026-07-22
- Director · Restricted Stock Units (RSUs) → Common StockAcquired 277grant · 2026-07-22
- Director · Restricted Stock Units (RSUs) → Common StockAcquired 277grant · 2026-07-22
- Director · Restricted Stock Units (RSUs) → Common StockAcquired 277grant · 2026-07-22
- Director · Restricted Stock Units (RSUs) → Common StockAcquired 277grant · 2026-07-22
- Director · Restricted Stock Units (RSUs) → Common StockAcquired 277grant · 2026-07-22
- EVP & CFO · Restricted Stock Units (RSUs) → Common StockAcquired 8 082grant · 2026-05-29
- EVP & CFO · Restricted Stock Units (RSUs) → Common StockAcquired 3 019grant · 2026-05-29
- EVP & Chief HR Officer · Restricted Stock Units (RSUs) → Common StockDisposed 679exercise · 2026-05-23
- EVP, Chief Strategy & BDO · Restricted Stock Units (RSUs) → Common StockDisposed 594exercise · 2026-05-23
- SVP, Controller & CAO · Restricted Stock Units (RSUs) → Common StockDisposed 136exercise · 2026-05-23
- EVP, CIO and CTO · Restricted Stock Units (RSUs) → Common StockDisposed 136exercise · 2026-05-23
- Director, Chief Executive Officer · Restricted Stock Units (RSUs) → Common StockDisposed 4 579exercise · 2026-05-23
- EVP & CFO · Restricted Stock Units (RSUs) → Common StockDisposed 1 476exercise · 2026-05-23
- SVP, Controller & CAO · Restricted Stock Units (RSUs) → Common StockDisposed 91exercise · 2026-05-21
- EVP and Chief Legal Officer · Restricted Stock Units (RSUs) → Common StockDisposed 724exercise · 2026-05-21
- EVP, CIO and CTO · Restricted Stock Units (RSUs) → Common StockDisposed 483exercise · 2026-05-21
- EVP & CFO · Restricted Stock Units (RSUs) → Common StockDisposed 1 207exercise · 2026-05-21
- Director, Chief Executive Officer · Restricted Stock Units (RSUs) → Common StockDisposed 3 500exercise · 2026-05-21
- EVP & Chief HR Officer · Restricted Stock Units (RSUs) → Common StockDisposed 531exercise · 2026-05-21
- EVP, Chief Strategy & BDO · Restricted Stock Units (RSUs) → Common StockDisposed 423exercise · 2026-05-21
- EVP and Chief Legal Officer · Restricted Stock Units (RSUs) → Common StockDisposed 677exercise · 2026-05-20
- EVP, CIO and CTO · Restricted Stock Units (RSUs) → Common StockDisposed 463exercise · 2026-05-20
- EVP, Chief Strategy & BDO · Restricted Stock Units (RSUs) → Common StockDisposed 324exercise · 2026-05-20
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
Source documents
- Millennium & Copthorne Hotels New Zealand Ltd Market data — financials · 2026-05-28
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,85 %$2 526M
- Investment Managers · as of 2026-03-310,65 %$2 651M
- Investment Managers · as of 2026-03-310,61 %$1 135M
- Investment Managers · as of 2026-03-310,60 %$1 838M
- Investment Managers · as of 2026-03-310,36 %$784M
- Institutional Investor · as of 2026-03-310,27 %$544M
- Funds · as of 2026-03-310,20 %$1 291M
- Investment Managers · as of 2026-03-310,17 %$4 965M
- Investment Managers · as of 2026-03-310,17 %$1 265M
- Institutional Investor · as of 2026-03-310,16 %$3 118M
- Investment Managers · as of 2026-03-310,16 %$2 502M
- Investment Managers · as of 2024-06-300,15 %$6 700M
- Investment Managers · as of 2026-03-310,15 %$1 129M
- Investment Managers · as of 2025-12-310,14 %$9 929M
- Institutional Investor · as of 2026-03-310,13 %$714M
- Investment Managers · as of 2026-03-310,13 %$236M
- Investment Managers · as of 2026-03-310,12 %$818M
- Investment Managers · as of 2026-03-310,12 %$1 990M
- Investment Managers · as of 2026-03-310,12 %$205M
- Institutional Investor · as of 2026-03-310,12 %$498M
- Investment Managers · as of 2024-12-310,11 %$404M
- Investment Managers · as of 2026-03-310,11 %$166M
- Investment Managers · as of 2026-03-310,09 %$527M
- Investment Managers · as of 2026-03-310,09 %$130M
- Brokerage Firms · as of 2026-03-310,09 %$287M
- Institutional Investor · as of 2022-09-300,09 %$0M
- Investment Managers · as of 2026-03-310,08 %$1M
- Brokerage Firms · as of 2026-03-310,08 %$398M
- Investment Managers · as of 2026-03-310,06 %$308M
- Investment Managers · as of 2026-03-310,06 %$268M
- Investment Managers · as of 2026-03-310,06 %$213M
- Investment Managers · as of 2026-03-310,05 %$96M
- Institutional Investor · as of 2026-03-310,05 %$101M
- Investment Managers · as of 2026-03-310,01 %$35M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
Insider activity
Net selling0 buys · 9 sellsnet -$23,6M10 insiders · last 365d
- Director · Common StockOther 277 @ $814,04$225K · 2026-07-22
- Director · Common StockOther 277 @ $814,04$225K · 2026-07-22
- Director · Common StockOther 277 @ $814,04$225K · 2026-07-22
- Director, Chief Executive Officer · Common StockSold 8 463 @ $793,56$6,7M · 2026-07-07
- Director, Chief Executive Officer · Common StockSold 8 463 @ $775,13$6,6M · 2026-06-17
- Director, Chief Executive Officer · Common StockSold 4 929 @ $763,00$3,8M · 2026-06-09
- SVP, Controller & CAO · Common StockSold 133 @ $764,00$102K · 2026-06-05
- EVP, Chief Strategy & BDO · Common StockSold 699 @ $735,27$514K · 2026-06-02
- EVP, Chief Strategy & BDO · Common StockSold 123 @ $735,50$90K · 2026-06-01
- EVP & Chief HR Officer · Common StockSold 1 810 @ $735,50$1,3M · 2026-06-01
- EVP and Chief Legal Officer · Common StockSold 3 550 @ $761,09$2,7M · 2026-05-26
- EVP, Chief Strategy & BDO · Common StockSold 2 388 @ $761,09$1,8M · 2026-05-26
- EVP, Chief Strategy & BDO · Common StockOther 234 @ $766,08$179K · 2026-05-23
- EVP, CIO and CTO · Common StockOther 54 @ $766,08$41K · 2026-05-23
- EVP, CIO and CTO · Common StockOther 136 · 2026-05-23
- SVP, Controller & CAO · Common StockOther 41 @ $766,08$31K · 2026-05-23
- SVP, Controller & CAO · Common StockOther 136 · 2026-05-23
- EVP, Chief Strategy & BDO · Common StockOther 594 · 2026-05-23
- EVP & Chief HR Officer · Common StockOther 268 @ $766,08$205K · 2026-05-23
- EVP & Chief HR Officer · Common StockOther 679 · 2026-05-23
- EVP & CFO · Common StockOther 581 @ $766,08$445K · 2026-05-23
- EVP & CFO · Common StockOther 1 476 · 2026-05-23
- Director, Chief Executive Officer · Common StockOther 1 831 @ $766,08$1,4M · 2026-05-23
- Director, Chief Executive Officer · Common StockOther 4 579 · 2026-05-23
- EVP and Chief Legal Officer · Common StockOther 285 @ $766,50$218K · 2026-05-21
Short positioning
3.9Mshares short-5.8% vs prior
4.12days to cover
44.6%short of daily vol
229fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Index membership
S&P 500United States
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
MCK.NZCanonical
NZX · NZD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Relationship graph
This companySectorPartnersSubsidiaries
Evidence & claims
From filings & derived data- Gross margin (FY 2026-03-31): 3.6%Derived (calculated)
- Operating income (YoY) (2026-03-31 vs 2025-03-31): 40.5%Derived (calculated)
- Gross profit (YoY) (2026-03-31 vs 2025-03-31): 9.2%Derived (calculated)
- Cost of revenue (YoY) (2026-03-31 vs 2025-03-31): 12.5%Derived (calculated)
- Net income (YoY) (2026-03-31 vs 2025-03-31): 44.5%Derived (calculated)
- EPS (diluted) (YoY) (2026-03-31 vs 2025-03-31): 49.2%Derived (calculated)
- Operating cash flow (YoY) (2026-03-31 vs 2025-03-31): 1.2%Derived (calculated)
- EPS (basic) (YoY) (2026-03-31 vs 2025-03-31): 49.1%Derived (calculated)
- Revenue (YoY) (2026-03-31 vs 2025-03-31): 12.4%Derived (calculated)
- Capex (YoY) (2026-03-31 vs 2025-03-31): -18.8%Derived (calculated)
- Net margin (FY 2026-03-31): 1.2%Derived (calculated)
- Operating income (annual): USD 6.21BSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES 38SEC XBRL filing
- Total operating expenses (annual): USD 8.34BSEC XBRL filing
- Net income (annual): USD 4.76BSEC XBRL filing
- Revenue (annual): USD 403.43BSEC XBRL filing
- Cost of revenue (annual): USD 388.88BSEC XBRL filing
- Pre-tax income (annual): USD 6.2BSEC XBRL filing
- Gross profit (annual): USD 14.55BSEC XBRL filing
- Operating cash flow (annual): USD 6.16BSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES 39SEC XBRL filing
- Capex (annual): USD 436MSEC XBRL filing
- Current ratio (FY 2025-12-31): 0.88xDerived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 57.9%Derived (calculated)
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ2 2026 earnings (expected) estimated date
2026-07-22INSIDERWilson-Thompson Kathleen transacted 277 sh — Director ~$225k
2026-07-22INSIDERCaruso Dominic J transacted 277 sh — Director ~$225k
2026-07-22INSIDERMartinez Maria transacted 277 sh — Director ~$225k
2026-07-22INSIDERLerman Bradley E acquired 277 sh Restricted Stock Units (RSUs) — Director
2026-07-22INSIDEROZAN KEVIN M acquired 277 sh Restricted Stock Units (RSUs) — Director
2026-07-22INSIDERGerberding Julie L. acquired 277 sh Restricted Stock Units (RSUs) — Director
2026-07-22INSIDERDunsire Deborah acquired 277 sh Restricted Stock Units (RSUs) — Director
2026-07-22INSIDERHinton James H. acquired 277 sh Restricted Stock Units (RSUs) — Director
2026-07-22INSIDERDunbar Webster Roy acquired 277 sh Restricted Stock Units (RSUs) — Director
2026-07-22INSIDERDoughtie Lynne M acquired 277 sh Restricted Stock Units (RSUs) — Director
2026-07-07INSIDERTYLER BRIAN S. sold 8.5k sh — Director, Chief Executive Officer ~$6.72M
2026-07-02 04:32 UTCFILINGMaterial 8-K
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: insider_flow_signal (90d)
2026-06-17 00:00 UTCINSIDER6 insider transactions — 2026-06 · net sell $12.4M
2026-06-17 00:00 UTCINSIDER6 insider transactions — 2026-06 · net sell $12.4M
2026-06-17INSIDERTYLER BRIAN S. sold 8.5k sh — Director, Chief Executive Officer ~$6.56M
2026-06-09INSIDERTYLER BRIAN S. sold 4.9k sh — Director, Chief Executive Officer ~$3.76M
2026-06-05INSIDERRutledge Napoleon B JR sold 133 sh — SVP, Controller & CAO ~$102k
2026-06-02INSIDERRodgers Thomas L sold 699 sh — EVP, Chief Strategy & BDO ~$514k
2026-06-01INSIDERRodgers Thomas L sold 123 sh — EVP, Chief Strategy & BDO ~$90k
2026-06-01INSIDERSmith LeAnn B sold 1.8k sh — EVP & Chief HR Officer ~$1.33M
2026-05-29 00:00 UTCINSIDER55 insider transactions — 2026-05 · net sell $9.3M 19 derivative
2026-05-29 00:00 UTCINSIDER55 insider transactions — 2026-05 · net sell $9.3M 19 derivative
2026-05-29INSIDERCheung Kenny K acquired 3.0k sh Restricted Stock Units (RSUs) — EVP & CFO
2026-05-29INSIDERCheung Kenny K acquired 8.1k sh Restricted Stock Units (RSUs) — EVP & CFO
2026-05-26INSIDERLau Michele sold 3.5k sh — EVP and Chief Legal Officer ~$2.70M
2026-05-26INSIDERRodgers Thomas L sold 2.4k sh — EVP, Chief Strategy & BDO ~$1.82M
2026-05-23INSIDERRodgers Thomas L transacted 234 sh — EVP, Chief Strategy & BDO ~$179k
2026-05-23INSIDERFraga Francisco transacted 54 sh — EVP, CIO and CTO ~$41k
2026-05-23INSIDERFraga Francisco transacted 136 sh — EVP, CIO and CTO
2026-05-23INSIDERRutledge Napoleon B JR transacted 41 sh — SVP, Controller & CAO ~$31k
2026-05-23INSIDERRutledge Napoleon B JR transacted 136 sh — SVP, Controller & CAO
2026-05-23INSIDERRodgers Thomas L transacted 594 sh — EVP, Chief Strategy & BDO
2026-05-23INSIDERSmith LeAnn B transacted 268 sh — EVP & Chief HR Officer ~$205k
2026-05-23INSIDERSmith LeAnn B transacted 679 sh — EVP & Chief HR Officer
2026-05-23INSIDERVitalone Britt J. transacted 581 sh — EVP & CFO ~$445k
2026-05-23INSIDERVitalone Britt J. transacted 1.5k sh — EVP & CFO
Showing the 40 most recent of 84 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage